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1. Introduction 
Breast cancer is the most common cancer and the second leading cause of cancer deaths in 
women worldwide. Breast cancer statistics in the US shows a bimodal distribution 
consisting of early-onset and late-onset patients. Although the incidence of early-onset 
breast cancer in western population is low, the survival rate is significantly poorer before 40 
years old (Yankaskas, 2005). Bonnier and his colleagues showed that the breast cancer 
patients under 35 years old also have poorer prognostic and possess the following 
characteristics: (1) a higher frequency of undifferentiated tumors, (2) histoprognostic grade-
III cancer, (3) microscopic lymph-node involvement and (4) negative hormonal receptor 
status (Bonnier et al., 1995).   
Although incidence rate of breast cancer has been decreasing in the US, this happens only in 
the late-onset age group (Benz, 2008). Asian women have significant lower incidence rate of 
breast cancer (about 25/100000 in Eastern Asia) than the western countries (about 
90/100000 in Western Europe) but the rate of incidence is increasing steadily with the 
improvement of economics in the area. In Taiwan, the incidence of breast cancer has 
dramatically increased from about 13/100000 in 1980 to 49/100000 in 2005 (Chang et al., 
2008). The increase in breast cancer in Asia is different from that of western countries in that 
the incidence of premenopausal breast cancer is proportionally higher in the Asian women. 
Similar trend of early-onset breast cancer is found in Africa (Kruger et al., 2007).    
According to clinical statistics, breast cancer patients in Taiwan are mainly identified 10 
years younger than their counterparts in the western countries. Compared with the late-
onset group, the early-onset breast cancer (age < or = 40) has a more aggressive clinical 
behavior, and its five-year survival rate for each stage is much poorer. One unique feature in 
                                                 
*Ching Cheng1, Chian-Feng, Chen2,Yiin-Jeng Jong4, Chien-Yi Tung3, Yann-Jang Chen4, 
Sheng Wang-Wuu4, Ling-Hui Li4, Shih-Feng Tsai4, Mei-Hua Tsou5, Skye H. Cheng5, Chii-Ming Chen5, 
Andrew T. Huang5, Chi-Hung Lin3 and Ming-Ta Hsu1,2 
1Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan 
2VGH-YM Genome Center, National Yang-Ming University, Taipei, Taiwan 
3 Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan 
4Institute of Genome Sciences, National Yang-Ming University, Taipei, Taiwan 
5Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan 
www.intechopen.com
 
Breast Cancer – Recent Advances in Biology, Imaging and Therapeutics 
 
148 
Taiwan is the large proportion of early-onset breast cancer (Cheng et al., 2000). Compared 
with the late-onset group, the early-onset breast cancer (age < or = 40) has a more aggressive 
clinical behavior, and its five-year survival rate for each stage is much poorer. The early-
onset breast cancer has poorer prognostic features. Standard pathologic factors are not good 
predictors of their outcome. Several studies have correlated the breast cancer subtypes with 
early-onset breast cancer recently(Anders et al., 2008; Lin et al., 2009; Sorlie et al., 2003; 
Sotiriou et al., 2003). The classification of subtypes has been shown to provide prognostic 
information and etiologic mechanisms of breast cancer. In Taiwan, the young women breast 
cancer tends to be more luminal A type with higher ER and PR expression and less basal-
like subtype than that of the older women (Cheng et al., 2000; Lin et al., 2009), but with 
higher risk of second primary malignancy and worse prognosis (Lee et al., 2008; 
Mellemkjaer et al., 2006; Yu et al., 2006). This feature is quite distinct from that of western 
developed countries with high prevalence of more aggressive basal-like breast cancer in 
young women. In western populations, younger women are more likely to have biologically 
aggressive breast cancer as shown by higher proportions of ER-negative and histologic 
grade III tumors compared with older patients (Anderson et al., 2002; Anderson et al., 2001; 
Colleoni et al., 2002). Anders and the colleagues also reported that more aggressive 
subtypes, such as basal-like subtype, would be over-represented among breast cancer 
arising in early-onset patients, whereas older women would more commonly be diagnosed 
with luminal tumors in the USA (Anders et al., 2011).  The increasing incidence of breast 
cancer in the young women population is worrisome since they constitute a major labor 
force and are also potential mothers who need to take care of young children. It is therefore 
important to understand the epidemiological as well as genetic origin of the rising incidence 
of early-onset breast cancer with possible implications in prevention as well as 
diagnostic/prognostic applications.  
Etiological factors of breast cancer are complex. Reproductive history, diet, alcohol, and 
body size among others have been implicated (Jevtic et al., 2010; McTiernan et al., 2010; 
Phipps et al., 2011). Among these factors reproductive history has been found to be strongly 
correlated with breast cancer is reproductive history. Since the early observation of high 
incidence of breast cancer among nuns in eighteenth century nulliparity and older age at 
first birth have been strongly associated with incidence of breast cancer (Butt et al., 2009; 
Muti, 2005; Trichopoulos et al., 2008; Wu et al., 2011; Yaghjyan and Colditz, 2011). Both 
nulliparity and older age pregnancy and child birth are characteristics of developed 
countries and countries with rapid economic growth as in Taiwan. This may partly explain 
the rapid rise of this disease here. 
The association of reproductive history and breast cancer might be understood from 
hormone target theory (Adami et al., 1995; Adami et al., 1998; Cerliani et al., 2011; Trepp et 
al., 2010). Mammary gland formation consists of three stages: organogenesis, which grows 
from terminal end bud (TEB) to non-pregnant primary ductal system with cuboidal 
epithelial cells and is stimulated by prolactin; mature gland formation, with highly 
branched ducts and lobular buds; pregnancy gland formation, through the stimulation of 
several hormones with differentiation of lobular buds into fully differentiated type III 
lobules with milk secreting columnal cells. These complicated differentiation processes 
involve temporal controls from hormones, cytokines, specific transcription factors, growth 
factors as well as contribution from stromal elements including myoepithelial cells, base 
membrane and a collection of integrins (Ahmad and Kumar, 2011; Chen and Capecchi, 1999; 
Chodosh et al., 1999; Flucke et al., 2010; Howell and Evans, 2011; Li et al., 2010; Okoh et al., 
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2011; Tamimi et al., 2011). As a major organ involved in pregnancy the major player in 
mammary gland development is hormone. Induction of cell differentiation by hormone 
during pregnancy provides protection against tumorigenesis because the epithelial cells 
become fully differentiated and are not susceptible to carcinogens. This explains the role of 
parity in breast cancer. The better protection for earlier pregnancy can be explained by the 
smaller hormone targets and the less chance to accumulate deranged cells. 
According to the hormone target theory, stimulation of cell growth of undifferentiated 
epithelial cells in immature mammary gland may provide a mechanism for early-onset 
breast cancer. The predominance of immature epithelial cells in embryo provides the target 
for the initiation of tumorigenesis when intrauterine hormone concentration is high. Indeed, 
animal studies showed that undifferentiated TEB is the most susceptible to carcinogen for 
the formation of tumor (Bai and Rohrschneider, 2010; Roussos et al., 2010; Russo and Russo, 
1994). Recent evidence even points to the immature gland in utero as the target for the 
initiation of breast cancer (Brisken and O'Malley, 2010; Hardy et al., 2010; Hilakivi-Clarke 
and Clarke, 1998; Sanderson et al., 1998; Torres-Arzayus et al., 2010). 
Although there is intensive study of the genetic pathways involved in breast tumorigenesis, 
the genetic basis of the breast cancer in young women and the differences between early-
onset and late-onset tumors remain largely unknown. The different pathological features of 
the two types of cancer suggest that they have different genetic origin. In order to explore 
the genetic basis of early-onset and late-onset breast cancer, we analyzed the candidate 
genes associated with the chromosomal aberrations in these two types of cancer from data 
in the public domain as well as from our own array-CGH data from the patients in Taiwan 
through literature search of involvement of genes in the aberration regions.  Furthermore, 
the differential gene expression of these two types of cancer is analyzed by SAGE technique 
to deduce the genes that may be specifically related to early-onset cancer.     
2. Comparison of genomic aberrations between early- and late-onset breast 
cancer 
Breast cancer frequently contains amplification in several regions of chromosomes. Recent 
advances in high resolution array-CGH analysis and the availability of human genome 
sequence enabled finding candidate genes involved in breast cancer from these 
chromosomal aberration regions. We are interested in studying genes associated with early-
onset (age <40) breast cancer which has become a major health concern in Taiwan. Early-
onset breast cancer has poor prognosis compared with late-onset (age >70) breast cancer and 
genomics analysis indicated that they have different chromosomal and genetic aberration 
profiles, suggesting they have different origins. In this article we summarized the current 
candidate genes involved in breast cancer from genomic data and presented data on genetic 
differences between the two types of breast cancer. The possible implication in the genetic 
differences is discussed.    
2.1 Review of chromosome aberrations in early- and late-onset breast cancer and 
candidate genes associated with tumorigenesis 
To explore the genes differentially associated with early-onset and late-onset breast cancers, 
we first collected the aCGH data in the Progenetix database (www.progenetix.net) (Baudis 
and Cleary, 2001; Boldt et al., 2010; Fridlyand et al., 2006; Reis-Filho et al., 2005) and 
reanalyzed the data. All the samples were regrouped based on the age of patients: younger 
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and elder groups were defined as less than 46 and more than 70 years old respectively. Then 
the frequency of copy number gains or losses (y axis) were plotted with the probes along 
with the chromosome order (x axis). As the frequency lower than 10% may reflect the 
randomly change dues to the genomic instability of tumor, we define gain or loss more than 
30% as significant aberrations. Early or late onset-specific aberrations were defined as gain 
or loss more than 30% and higher than the other group at least 15%. When these data are 
lined up chromosome-by-chromosome (Fig. 1), regions of chromosome aberrations common 
to both groups as well as specific to each group can be discerned (Table 1). Genes within 
each regions identified are then examined through literature search to identify candidate 
genes involved in breast carcinogenesis (Table 2, and 3). Genes that are either down-related 
or suppress tumorigenesis are in italic. 
 
 
Fig. 1. Chromosome aberrations in early- and late-onset breast cancer. 
 
 
Gains Losses 
Early onset 
Ch1 41~42Mb - - 
Ch1 148~157Mb - - 
Ch3 161~172Mb - - 
Ch7 150~151Mb - - 
Ch9 0~14Mb - - 
Ch13 103~112Mb - - 
Late onset Ch16 7~25Mb Ch16 74~81Mb 
Common 
Ch1 175~247Mb Ch8 3~32Mb 
Ch8 48~114Mb Ch11 108~114Mb 
Ch20 50~51Mb Ch17 0~9Mb 
Table 1. Aberrant chromosomal regions in Breast Cancer Patients. 
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Early- 
onset 
 
 
 
 
 
 
 
GAINS 
 
 
 
Chr1  
41~42Mb 
MIRN30E 
Chr1 
148~157Mb 
ECM1, HORMAD1, CTSS, CTSK, ARNT, PRUNE, 
S100A10, S100A11, FLG, HAX1, PYGO2, CKS1B, 
ADAM15, MUC1, NES, NTRK1 
Chr3 
161~172Mb 
PRKCI, SKIL 
Chr7 
150~151Mb 
ABCF2, RHEB 
KCNH2 
Chr9  
0-14Mb 
VLDLR 
 
Late- 
onset 
 
GAINS 
Chr16 
7~25Mb 
CIITA, SOCS1 
MIRN193B, PALB2 
LOSSES 
Chr16 
74~81Mb 
CNTNAP4, ADAMTS18, WWOX, HSD17B2 
Table 2. Aberrations in early-and late-onset breast cancer. 
Totally, there are 6 early-onset specific gains on the chromosomes 1 (41-42Mb; 148-157Mb), 3 
(161-172Mb), 7 (150-151), 9 (0-14Mb) and 13 (103-112Mb), one late-onset specific gain on 
chromosome 16(7-25Mb), three common gains on chromosomes 1 (175-247Mb), 8 (48-
114Mb) and 20 (50-51Mb). There is a late-onset specific loss in chromosome 16 (74-81Mb) 
and common loss on chromosomes 8 (3-32Mb), 11 (108-114Mb) and 17 (0-9Mb). Genes that 
have been shown to be involved in breast carcinogenesis in these regions through literature 
search are listed in Table 2 and 3. 
Interestingly, the early onset-specific aberrations contain more IGF-1 and ER signaling 
associated genes than the late onset. Candidate genes present in the IGF-1, ER and TGF-beta 
pathways in both groups of breast cancer patients are listed in Table 4.  
The association of ER genes with early-onset cancer is expected since these patients are 
premenopausal. Since IGF-1 pathway plays an important role in breast tumorigenesis, the 
genes specific for the late and early-onset cancer are depicted in Fig. 2 to illustrate their 
positions in the pathway.       
2.2 Clustering of breast cancer related genes in chromosome regions 
A striking feature of the analysis of genes associated with gain or loss in breast cancer 
chromosomes is that the regions often harbor breast cancer related genes in a cluster fashion 
and demarked by the presence of genes down-regulated or are anti-tumorigenic in breast 
cancer. 
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GAINS 
 
 
 
 
 
 
 
 
 
 
Chr1 
175~247Mb 
PTGS2, PLA2G4A, RGS2, KIF14, LAD1, TIMM17A, ELF3, 
UBE2T, JARID1B, ADIPOR1, ADORA1, PCTK3, IKBKE, 
MAPKAPK2, CD55, CD46, NEK2, DTL, ATF3, ESRRG, 
GPATCH2, TGFB2, DUSP10, ENAH, EPHX1, PARP1, 
WNT9A, WNT3A, ARF1, EXO1, AKT3, SMYD3 
RGSL1, RNASEL, RGS16, BTG2, KISS1, RASSF5, IL10, 
LAMB3, IRF6, PROX1, PTPN14, TLR5, T53BP2, FH, CHM 
 
 
 
Chr8 48~144Mb 
SNAI2, LYN, SDCBP, ASPH, COPS5, PRDM14, NCOA2, 
TPD52, FABP5, E2F5, WWP1, CPNE3, MMP16, CCNE2 
TSPYL5, MTDH, LAPTM4B, YWHAZ, CTHRC1, ANGPT1, 
EIF3E, EBAG9, TRPS1, RAD21, TNFRSF11B, HAS2, ATAD2, 
TRMT12, TATDN1, SQLE, MYC, PVT1, DDEF1, WISP1, 
PTP4A3 
CEBPD, PRKDC, RB1CC1, SOX17, CRH, VCPIP1, SGK3, 
SULF1, DECR1, TP53INP1, STK3, UBR5, DPYS, NOV, 
MTSS1, NDRG1 
 
 
 
 
 
LOSSES 
 
 
 
 
 
Chr8 3~32Mb 
ANGPT2, CTSB, EGR3, LOXL2, NKX3-1, STC1, CLU, PBK 
CSMD1, MCPH1, MSRA, GATA4, DLC1, MTUS1, ASAH1, 
NAT1, PSD3, LZTS1, PDLIM2, RHOBTB2, BNIP3L, EPHX2, 
DUSP4, PPP2CB, WRN, NRG1 
Chr11 108-
114Mb 
- 
PPP2R1B 
Chr17 0~9Mb MYBBP1A, PELP1, PLD2, NUP88,  
MIRN22, SMYD4, HIC1, MNT, ALOX15, CXCL16, PFN1, 
XAF1, MIRN195, MIRN497, CLDN7, GPS2, SHBG, ATP1B2, 
TP53 
Table 3. Aberrations in both early- and late-onset breast cancer. 
 
 IGF-1 Signaling Estrogen Receptor 
Signaling 
TGF-Beta Signaling 
Early onset 
specific 
aberrations 
IRS2, JAK2, PRKAG2, 
PRKCI, SHC1 
SHC1, HIST2H3C  
Late onset 
specific 
aberrations 
SOCS1   
Common 
aberrations 
AKT3, NOV, PIK3C2B, 
PIK3R5, PTK, YWHAE, 
YWHAZ 
 
H3F3A/H3F3B, 
HIST3H3, MED30, 
MED31, NCOA2, PELP1, 
POLR2A, POLR2K, 
PRKDC, TAF2, TAF5L 
TGFb2 
Table 4. The relationship of aberrant genes and IGF-1, ER, and TGF- signal pathways. 
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Fig. 2. IGF-1 signal pathway. 
For example, 198-201Mb in 1q32.1 contains eight genes related to breast tumorigenesis, 
KLF14, LAD1, TIMM17A, ELF3, UBE2T, JARID1B, ADIPOR1 and ADORA1 as well as a 
gene CARP1 that is over-expressed in cancers (Fig. 3 shows the distribution of genes 
positively correlated with breast cancer as red line and negatively correlated with breast 
cancer as green). We also observed the clustering of the genes that inhibits breast 
tumorigenesis or are down-regulated in breast cancer in chr17 0-9Mb region that is often 
deleted in breast cancer. These are mir-22, SMYD4, HIC1, MNT, ALOX15, CLCX16, PFN1, 
XAF1, mir-195, mir-497, CLDN7, GPS2, SHBG, ATP1B2, and TP53. The pro- and anti-
tumorigenesis genes are often found clustered together in a region of the chromosome.  
2.3 Comparison of chromosome aberrations between early-onset and late-onset 
breast cancers in Taiwan 
To investigate the gene aberrations between early-onset and late-onset breast cancer in 
Taiwan, we have used Vysis GenoSensor TM Array 300 microarray chip, containing 378 
target clone DNA (P1, BAC or PAC clones) representing regions that are important in 
cytogenetics and oncology, to analyze 15 early-onset and 15 late-onset breast cancer 
samples. The tissue samples of primary breast cancers were obtained by either biopsies or 
surgical excision from Koo Foundation Sun Yat- Sen Cancer Center (KF-SYSCC), Taipei, 
Taiwan. Instead of metaphase chromosome in conventional CGH, BAC or PAC DNAs are 
www.intechopen.com
 
Breast Cancer – Recent Advances in Biology, Imaging and Therapeutics 
 
154 
used as hybridization template in array- CGH, which can increase resolution up to 
approximate 100 kb. 
 
 
Fig. 3. Common genomic aberration in both early- and late-onset breast cancers. Left panel 
shows the amplified regions and right panel shows the deleted regions in breast cancers. 
The red and green lines represent the gene position in the genome. Red lines indicate genes 
positively correlated with breast cancer and green lines indicate negatively correlated with 
breast cancer. 
The genes present in the most frequent gain or loss regions of early-onset and late-onset 
breast cancer in Taiwan were analyzed by array-CGH. The genes related to breast cancer in 
these regions are shown in Table 5. There are two regions differentially gained or loss in 
late-onset and three regions differentially gained or loss in early-onset. As in the results 
above, the regions are marked by the presence of both pro- and anti-tumor genes (in italic) 
except 17q23 which is amplified in a subset of early-onset cancer but in none of the late-
onset cancer. We analyzed the genes of this region flanking our array-CGH BAC probes. It 
contains seven genes involved in breast tumorigenesis and represents a region of interest for 
early diagnosis of breast cancer in young women.     
2.4 SAGE analysis of gene expression in early- and late-onset breast cancer in Taiwan 
We analyzed 10325 SAGE Taq sequences, and classified SAGE data into two groups 
(evaluated significance by monte-carol algorthim). There are 460 genes related to the early-
onset group, and 214 genes involved in late-onset breast cancer.  
SAGE analysis found 12 breast cancer related genes highly prevalent in early-onset than late-
onset. Among these genes, cytokeratin 5 and 17 are basal cell markers and are often found in 
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basal-like and triple-negative breast cancer subtypes. Luminal specific cytokeratin KRT8 and 
KRT19 was also found to be enriched in early-onset cancer. This result suggests that there are 
two different subtypes, basal-like and luminal groups, of breast cancer in the early-onset 
samples we analyzed. Both tumor promoting and inhibiting genes are found expressed in the 
SAGE data. For example, KLK6 inhibits EMT and its expression is negatively correlated with 
breast cancer metastasis (Pampalakis et al., 2009) and FLNA (filamin A) is known to suppress 
breast cancer migration and invasion (Xu et al., 2010). The expression of the tumor suppressive 
CDH1, CDH13, CTNNB1, SFN, NDRG1 and PFN1 in early-onset tumor also suggests the less 
invasive nature. IGFBP4 is positively correlated with ER and PR but negatively correlated with 
Her2 and has better disease outcome (Mita et al., 2007). On the other hand, S100P and LCN2 
promote breast cancer progression. Whether the expression of tumor suppressive genes 
reflects the more benign nature of the early-onset breast cancer or due to mutations in these 
genes remain to be studied. Genes associated with tumor progression, metastasis and poor 
prognosis such as CXCR4, ERBB2, TOB1, EZH2, HIF1A, S100A7, are found significantly more 
expressed in the late-onset breast cancer. The overall expression pattern suggests that the late-
onset tumors are more advanced in tumorigenesis than that of the early-onset tumors which 
constitute mostly benign luminal A subtype in Taiwan.  
 
Cyto Location Gene related to breast cancer Early-onset 
(n=15) 
Late-onset 
(n=15) 
P- value 
Gains 
16p13.3 
 
 
 
MSLN, CACNA1H, PDPK1, SRMM2, 
TRAP1 
STUB1, TSC2, PKD1, ABCA3, 
DNAJA3 
6.67% 60.00% 0.0026 
8q11 
 
PRKDC, SNAI2 
CEBPD, MCM4, ST18, RB1CC1 
6.67% 46.67% 0.0176 
16q23.2 - 53.33% 13.33% 0.0251 
20q12-q13.1 
 
 
PLCG1, ADA, WISP2, CD40, 
NCOA3, SULF2, PREX1 
PTPRT, MYBL2, SDC4, UBE2C 
53.33% 13.33% 0.0251 
17q23 RPS6KB1, USP32, PAT1, PPM1D, 
BCAS3, TBX2, MRC2 
26.67% 0.00% 0.0498 
Losses 
1p36.22 - 6.67% 53.33% 0.0071 
22qtel PARVB, PARVG, PRR5, FNLN1, 
PPARA, GRAMD4 
6.67% 46.67% 0.0176 
1p13.1 VANGL1, VTCN1 0.00% 33.33% 0.0211 
11q22.3 PDGFD, ALKBH8, RDX 
CASP-12, -4, -5, -1, CUL5, ATM 
0.00% 26.67% 0.0498 
Xq25 XIAP, SMARCA1, APLN 
AIFMI 
0.00% 26.67% 0.0498 
Table 5. Significant difference between early- and late-onset breast cancers by array-CGH 
(aberrant genes correlated with early- or late-onset breast cancers were evaluated by using 
the Fisher’s exact test). 
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3. Conclusion 
In this report we show that early-onset breast cancer has different genetic alterations as 
compared with that of late-onset cancer, suggesting that different molecular pathways are 
involved in the generation of these two types of cancer. The genes strongly associated with 
early-onset breast cancer such as those in 17q23 amplicon may be useful for deducing the 
molecular mechanism of breast cancer in young women as well as for serving as candidate 
biomarkers.  
Early-onset breast cancer has been a major health concern and had poor prognosis 
compared with late-onset in Taiwan. We are interested in comparing the genome 
aberrations between early- and late-onset breast cancers. Although we study the genome 
aberrations in Taiwan, we also explore the public data which are associated with early-onset 
and late-onset breast cancers. The findings can help us to address early-onset breast cancer 
specific gene aberrations and explore the unique tumor biology in Taiwan through this 
broad view. 
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